- Allergy Therapeutics chief executive Manuel Llobet and finance director Ian Postlethwaite have been granted 905,000 and 452,500 options each, respectively, under the company's long term incentive plan for the three years ended 8 March 2015.

The options are exercisable between 11 March 2016 and 11 March 2026 at an exercise price of 0.1p per ordinary share.

Story provided by